Introduction
Despite their great diversity, the individual autoimmune diseases have certain features in common that may be taken as clues when considering what exactly goes awry when an autoimmune condition arises. At the top of this list is genetic predisposition, for which there is evidence in all the diseases examined. The pattern of inheritance is complex, indicating that several genes are involved. Although it is unlikely that the same genes are responsible for the predisposition to all autoimmune diseases, one gene complex-the major histocompatibility complex (MHC), in man the human leucocyte antigen (HLA)-has consistently been implicated as a major genetic risk factor. However, for none of the autoimmune diseases the genetic predisposition conferred by HLA is neither sufficient nor necessary for disease development. We have on the other hand almost no knowledge of the other genes involved in the induction of autoimmunity. Recent studies have provided evidence that the peripheral mechanisms of T cell tolerance are essential to control selfreactive T cells 1 and the elimination of peripheral mechanisms of self-tolerance may therefore result in the development of autoimmune disease. Hence, molecules affecting these mechanisms are obvious candidates for conferring risk to autoimmunity.
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4; CD152) is expressed exclusively on activated CD4
+ and CD8 + T cells and binds the same ligands, B7-1 and B7-2, as CD28 but with a 20-to 50-fold higher affinity. [2] [3] [4] However, whereas CD28 provides a critical costimulatory signal essential for the initiation and progression of T cell immunity, 5, 6 data indicate that CTLA-4 may actually function to down-regulate T cell function. 3, 7, 8 Studies have shown that the addition of Fab fragments of anti-CTLA-4 mAbs in vitro increases T cell proliferation and cytokine production, and in vivo administration of anti-CTLA-4 mAbs enhances T cell responses to nominal antigens, 9 intensifies superantigen-mediated cytotoxicity, 10 and augments antitumor activity. 11 In animal models of autoimmunity, such as diabetes, lupus, encephalomyelitis and rheumatoid arthritis, interference with the CTLA-4:B7 pathway, eg, by CTLA4-Ig or anti-B7 mAbs, affects disease progression, see below. Furthermore, the CTLA4 knockout mouse exhibits a profound spontaneous autoimmune disease. 12, 13 Together these observations suggest that the CTLA-4:B7 interaction plays a critical role in regulating self-tolerance, and hence in susceptibility to autoimmune disease.
In this review, we will discuss the role for CTLA-4 in autoimmune diseases. We will focus on the genetics of CTLA-4 and the possible role of genetic variation of the CTLA4 locus in susceptibility to autoimmune diseases.
Rodent autoimmune disease models and the CTLA4/CD28 system
Rodent autoimmune disease models are considered important tools for investigating both the putative functional aspects of various immune modulating processes, and the genetic background predisposing to various human autoimmune diseases.
The CTLA-4/CD28:B7 system has been investigated in vivo in several rodent models of autoimmune diseases [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] ( Table 1) . Interestingly, no studies have investigated the expression of the CTLA-4 molecule on cells infiltrating the target organ(s) in animal models of autoimmune (1) Early: at age 2-3 weeks, Early treatment with CTLA4-Ig Anti-B7-1 and anti-treatment every 2 day for 2 wks. prevents development of IDDM but B7-2 i.p.
(2) Late: at 80 days, treatment had no effect on the severity of every 3 day for ෂ10 wks.
insulitis. Late CTLA4-Ig treatment had no effect on the development of IDDM. diseases. Such studies have been carried out only on tissues in a limited number of human diseases (see below). The general approach for intervening with CTLA-4/ CD28:B7 system has been various ways of blocking the CTLA-4:B7, the CD28:B7 or the CTLA-4/CD28:B7 interaction. Only studies investigating the role of antibodies against CTLA-4 and antibodies against both the B7-1 and the B7-2 receptors and studies investigating the functional impact of CTLA4-Ig are evaluated, since interpretation of partial blockage experiments is difficult. Various combinations of recombinant human and recombinant mouse CTLA-4 proteins with human and mouse immunoglobulin (Ig) have been constructed, and differences in these constructs may have implications for the effect of treatment, at least in murine disease models. 15 Several studies suggest that blocking the CTLA-4:B7 pathway interferes with disease progression in wellcharacterised animal models of experimental allergic encephalomyelitis (EAE)-a model for human multiple sclerosis, insulin-dependent diabetes mellitus (IDDM), systemic lupus erythematosus (SLE), and collageninduced arthritis (CIA), for details see Table 1 . In addition, the timing of intervention is crucial to the effect. Generally, early treatment prevents or reduces the severity of disease, whereas treatment at or after clinical onset has little effect, although some divergences are obvious.
Genetics of CTLA4
The human CTLA4 maps to chromosome 2q33. 34 The gene exists as a single copy per haploid genome. It comprises 3 exons in addition to the leader sequence. 34, 35 The 5Ј region of the gene includes the sequence encoding the leader sequence, a conserved Kozak consensus sequence with the ATG (Met) initiation of translation signal, an inframe stop codon 26 bp upstream this ATG, and a TATA box 75 bp upstream the stop codon. 35 CTLA-4 is encoded as a 223 amino acid precursor protein. The signal sequence of ෂ37 amino acids is cleaved during biosynthesis. The mature protein contains a 124 amino acid extracellular region with homology to an Ig V-like domain, a 173 26 amino acid transmembrane region and a 36 amino acid cytoplasmic tale. Following the coding part of exon 3, is a 3Ј untranslated region (UTR) of about 1150 bp which comprises a stretch of almost 30 AT-repeats (see below). Exons 1 and 2 are separated by a 0.5 kb intron, and exons 2 and 3 are separated by a 1.1 kb intron. 35 The human CTLA4 sequence encodes two transcripts of 1.8 and 0.8 kb, respectively, which have alternative polyadenylation sites. 35 The longer transcript contains the repeated AU-motif.
As in the mouse, the human CTLA4 and CD28 genes are closely linked. They are separated by only 25 to 150 kb. 36 The homology between the mouse and human CTLA4 genomic sequence is 78%, and the homology at the protein level is 74% (at precursor protein level). The multiple homologies between the CTLA4 and CD28 genes and products in the mouse and in the human, strongly suggest that CTLA4 and CD28 are the result of a gene duplication. A duplication that must have occurred before speciation, but sufficiently recent to account for homologies between both molecules. Since the corresponding 5Ј and 3Ј flanking sequences are homologous between species but not between molecules, this duplication most likely took place before speciation to allow for divergence. Importantly, differences in flanking sequences might also suggest different regulatory mechanisms for the two genes.
No thorough mutation scanning covering the entire CTLA4 has been published. Deichmann et al 37 screened the regulatory and coding regions. However, it was not clear how the coding region was screened, and for the promoter region, how many individuals were screened by single stranded confirmation polymorphism (SSCP). 37 Ligers et al 38 screened the promoter, exon 1 and 2 for mutations in eight multiple sclerosis patients by sequencing.
Three polymorphisms of the CTLA4 locus have been reported and all of these have been tested in several autoimmune diseases (see below).
The first polymorphism to be identified was the dinucleotide repeat polymorphism of exon 3. 39 This polymorphic (AT) n repeat begins at bp 642 of exon 3 of the human CTLA4 gene. 34 At least 23 different alleles ranging from 7 to 30 AT repeats have been identified. 40 The allele nomenclature has varied between different reports, primarily based on different detection assays. Some authors have used the length of the amplicon to denote alleles, eg, 104 bp, 106 bp, etc. Others have used motility units (mu) based on automated fragment analysis readings, and finally some authors have used the number of ATrepeats to assign an unambiguous nomenclature. The polymorphism is highly informative with a heterozygosity of approximately 0.93 and a polymorphism information content (PIC) of 0.91.
The second polymorphism reported was a G to A transition at position 49 (G49A) of exon 1. This single nucleotide polymorphism (SNP) leads to an alanine to threonine amino acid substitution of codon 17 of the leader peptide (A17T). 41 The polymorphism is easily tested by a PCR-RFLP based assay, 40, 41 and has a heterozygosity of approximately 0.44 and a PIC of 0.35.
The third polymorphism was identified by Deichmann et al. 37 This is a C to T transition at position −318 (C-318T) of the promoter sequence. Also this polymorphism is eas-
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ily tested by a PCR-RFLP based assay. 37 The heterozygosity is approximately 0.15 and the PIC = 0.14.
Strong linkage of the promoter and exon 1 polymorphisms has been demonstrated. 42 The C-318 allele is common with both exon 1 alleles, whereas T-318 is strongly linked to the A49 allele. Several studies have shown that strong linkage between the G49 allele and the 106 bp allele of the 3ЈUTR polymorphism exists. 40, 41 Only few preliminary data exist to address the possible functional significance of these polymorphisms. One study suggested a correlation between the exon 1 SNP and CTLA4 messenger ribonucleic acid (mRNA) levels in human peripheral blood mononuclear cells, 43 whereas another study was unable to demonstrate any significant correlation between the exon 1 SNP or the 3ЈUTR microsatellite and gene expression. 44 However, both studies are preliminary and based on relatively few analysed samples, and further studies addressing this issue are warranted.
Genome-wide scans in autoimmune human diseases and rodent disease models
In the past decade, and in particular in the last few years, a large number of genome-wide scans in both human autoimmune diseases and in rodent disease models of human autoimmune diseases have been performed. In all the human autoimmune diseases investigated and reviewed in the present paper at least some degree of susceptibility to disease have been conferred by the gene(s) of the HLA region on 6p21. However, the complete genetic predisposition to disease could not be explained by susceptibility conferred by the 6p21 locus. Hence, other chromosomal loci were expected to harbour genes of importance for the development of these diseases. Suggestive evidence for linkage (MLS Ͼ 1.0) to the CTLA4 region was found only in four human studies (Table 2 ). In a small study, linkage between markers on 2q33 and asthma was demonstrated in a Hispanic population, but not in African-American and Caucasian patients. 49 Demonstration of linkage in a Mediterranean population, but not in other populations, is a striking observation in view of the findings in linkage studies of the CTLA4 3ЈUTR (AT)-repeat in IDDM. In the first study of linkage between the CTLA4 3ЈUTR repeat and IDDM, Nisticó et al 41 found evidence for linkage in 48 Italian families. Since this observation, no other studies have found linkage by means of conventional affected sib-pair analysis between this polymorphism and IDDM. However, in studies using allelic transmission analyses, increased transmission of alleles predisposing to IDDM are mainly seen in Mediterranean populations 92 with some variation. 40 In a large US and UK material, linkage disequilibrium by means of transmission disequilibrium test (TDT) analysis was found, but no linkage by means of identity by descent (IBD) analysis. 93 Concannon et al 51 reported linkage of the 2q31-q34 region but was not able to demonstrate linkage of D2S1391, the closest linked marker of CTLA4 to IDDM. This marker, however, linked to (MLS 2.1) SLE in European Caucasians, 79 and Gaffney et al 59 also found linkage to the 2q21-q33 region in SLE families of mainly Caucasoid origin in their study. In genome-wide scans of murine disease models, linkage to 
Human (Caucasians, US) D2S1391 2q32 79
Asthma Human (Hispanics) NA 2q33 49
All genome-wide scans in human and rodent immune mediated diseases were reviewed. Humans studies demonstrating a MLS Ͼ1.0 for a region harbouring the CTLA4 locus on 2q33 and rodent studies displaying significant linkage to a region including the Ctla4 locus on chr. 1, 30.1 cM from the centromere (MGI: 88556) in mice are listed in the table. The Ctla4 locus has not been mapped in rat but genes mapped up-and downstream the human CTLA4 locus on 2q33 and genes mapped up-and downstream the muine Ctla4 locus on the murine chr. 1 are mapped to the rat chr. 9 (ftp://ftp.informatics.jax.org/pub/informatics/reports/HMDFRat2.sql.rpt.). Thus, studies involving rat crosses have been investigated for loci on chr. 9 linking to autoimmunity, but no studies found linkage to the relevant region. Bcl2, B cell leukaemia/lymphoma 2 locus; IDDM, insulin-dependent diabetes mellitus; NA, not available from article; NOD, non-obese diabetic mice; SLE, systemic lupus erythematosus; Vil, villin gene. diabetes development, 60 insulitis 60 and apoptosis resistance in lymphocytes in non-obese diabetic (NOD) mice 50 have been demonstrated, with maximum linkage to the marker D1Mit5. In the BXSB murine SLE model, the same locus and marker, showed maximal linkage to nephritis development. 65 All these intervals overlap with the diabetes-linked Idd5 region in the NOD mouse. 94 A large number of whole and partial genome scans in murine models of SLE have found disease-linked loci on chromosome 1. Some of these were originally suggested to overlap the Idd5 locus, but more advanced mapping have localised the susceptibility loci distal to Idd5, reviewed in Vyse and Kotzin. 95 The present data from genome-wide scans suggest that a loci predisposing to autoimmunity, at least to IDDM and SLE, may be located in the CTLA4 region. When interpreting the results of genome scans it should be emphasised that the majority of immune mediated diseases seem to have polygenic susceptibility. Thus, genome scans are unlikely to provide significant linkage for minor susceptibility loci, which may only modify risk, as learned by the lesson from studies in IDDM. 40, 51, 77, 92, 93 The role of CTLA4 in human autoimmune diseases Autoimmune disease arises when the immune response is directed against a specific organ or a number of organs and systems within an individual. Therefore, autoimmune diseases are often categorised in two groups, 'organ-specific' or 'non-organ-specific'. Organ-specific autoimmune diseases include the autoimmune thyroid diseases (AITD), IDDM and multiple sclerosis (MS), whereas non-organ-specific diseases include systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Autoimmune diseases tend to cluster within families and it is not uncommon that patients are diagnosed with more than one autoimmune disease.
Inheritance of autoimmune disorders are in general very complex and most likely due to the presence of multiple susceptibility genes, and existence of modulatory environmental factors.
Using the candidate gene approach, ie, knowledge derived from animal model studies and obvious biochemical/physiological functions of CTLA-4 in the immune response, the role of CTLA4 has been investigated in various human autoimmune diseases. Originally, association between CTLA4 and autoimmune disease was demonstrated in a case-control study involving patients with Graves' disease. 96 The three known polymorphisms of the CTLA4 gene have all been investigated for linkage and/or association in a large number of human autoimmune diseases.
Autoimmune thyroid diseases (AITD)
Autoimmune thyroid diseases are among the most common human autoimmune disorders, affecting up to 5% of the general population. 97 AITD include two related disorders, Graves' disease (GD) and Hashimoto's thyroiditis (HT). GD and HT are thought to share common pathogenetic mechanisms, which include autoimmune reactions to epithelial cells mediated by both soluble and cellular mechanisms. 98 Linkage of HLA susceptibility genes with AITD have only been confirmed in some ethnic groups 99 suggesting that the HLA locus has only minor influence on the overall genetic predisposition. Although the two diseases share many pathogenic components, they have very different phenotypes.
Graves' disease (GD)
Graves' disease is immunologically characterised by lymphocytic infiltration of the thyroid gland and by immune system activation with raised levels of circulating activated T lymphocytes and thyroid-specific autoantibodies. These antibodies, which are directed against the thyroid follicular cell membrane thyrotropin receptor, stimulate thyroid function, thus causing the disease phenotypehyperthyroidism. 100 GD usually presents in the fourth decade of life and is reported to be seven to 10 times more common in women than men. Although most cases of GD occur in unrelated individuals (sporadic), 10-20% appear to cluster in families. 101 In a large Danish twin study of hyperthyroidism (assumed to be primarily GD), the concordance rate for monozygotic and dizygotic twins were 76% and 11%, respectively. 102 The CTLA4 locus is the only non-HLA locus for which association with GD has been repeatedly demonstrated. In 1995, Yanagawa et al 96 reported evidence for association with the CTLA4 3ЈUTR-microsatellit in a Caucasian population. Linkage 103, 104 and association 92,103-108 of the CTLA4 exon 1 polymorphism with GD has been found in several populations, although there seems to be some inconsistencies, probably due to population heterogeneity (Table 3 ). Few studies of the 3ЈUTR 109 and the C-318T 110,111 polymorphisms have also been published (Table 3 ).
Hashimoto's thyroiditis (HT)
The most common form of AITD is Hashimoto's thyroiditis, which manifests by hypothyroidism. HT is characterised by infiltration of the thyroid by lymphocytes, gradual destruction of the gland, and production of various secondary polyclonal thyroid autoantibodies, notably antithyroid peroxidase and antithyroglobulin. 112 The incidence of clinical evident disease reported is approximately 69 per 100 000. 113 However, this figure greatly underestimates the actual incidence, since histologic evidence of the disease has been observed in 2% of unselected Caucasian females at autopsy. 114 Only few genetic studies have been performed in HT. The majority of these have focused on the influence of the HLA region. The CTLA4 polymorphisms have been investigated in several case-control studies [108] [109] [110] [111] 115 (Table 3) . Even though the results are conflicting, there seems to be some evidence supporting an association between CTLA4 and HT.
Postpartum thyroiditis (PPT)
Postpartum thyroiditis is an autoimmune thyroid disease, and is believed to be caused by a combination of genetic and environmental factors. The immunological features of this disorder include the presence of thyroid peroxidase and less commonly thyroglobulin autoantibodies, abnormalities in the circulating T cell population, and goitre with lymphocytic infiltration similar to other forms of autoimmune thyroid disease. [116] [117] [118] PPT affects 4-6% of women in the years following delivery. 119 Permanent hypothyroidism is observed in ෂ25% of the women followed for several years after clinical resolution of PPT. 120 Significant differences in prevalence between ethnic groups have been reported. 121 Results from genetic studies of the HLA region in PPT have been conflicting. 122, 123 As the CTLA4 polymorphisms associate with AITD, CTLA4 are considered a putative candidate gene in PPT. However, a population-based case-control study revealed no evidence for association between the CTLA4 3ЈUTR polymorphism or any subgroups of PPT patients 124 (Table 3 ).
Addison's disease (AD)
Addison's disease results from the autoimmune destruction of the adrenal glands leading to dysfunction of ster-oidogenesis. The prevalence of AD in the general population is 3-6 per 100 000. The disease can develop independently or as part of autoimmune polyglandular syndrome type I (APS1) or type II (ASP2) in which it occurs with other autoimmune diseases. 101 In ASP1, AD occurs most commonly with chronic mucocutaneous candidiasis and hypoparathyroidism. ASP2 comprises a combination of AD with either autoimmune thyroiditis or insulin-dependent diabetes mellitus, or both.
125 ASP1 is an autosomal recessive trait with no association of the MHC region, whereas ASP2 and isolated AD have shown an association with HLA class II and III gene polymorphisms. [126] [127] [128] Two studies have investigated the genetic role of CTLA4 in AD. Donner et al 115 analysed 76 German Addison patients for the CTLA4 exon 1 polymorphism and found no overall association between the polymorphism and AD (Table 3) . However, when stratified for HLA risk alleles, they found a significant association. 115 English, Norwegian, Finnish and Estonian patients have been analysed for association of the different subgroups of AD with the CTLA4 106 bp allele, but significant association was found only in the English patients 125 ( Table 3) .
Insulin-dependent diabetes mellitus (IDDM)
Insulin-dependent diabetes mellitus is characterised by immune-mediated selective destruction of the pancreatic ␤-cells. IDDM may develop throughout life but peaks in childhood. The prevalence in most Caucasian populations is 0.4%. Most studies of monozygotic twins [129] [130] [131] [132] have shown that the majority of co-twins of IDDM patients are not diabetic, although a more recent report from Denmark showed a cumulative probandwise risk from birth to age 35 years of 70%. 133 IDDM was the first multifactorial disease to be studied by the whole genome linkage analysis approach, 54, 64 and several non-HLA IDDM susceptibility loci (IDDM2-17) have showed some evidence for linkage with the disease. CTLA4 is from a functional point of view 1 and through mapping studies considered the most likely known candidate gene for IDDM12 on 2q33. 134 In 1996, Nisticó et al 41 reported evidence for linkage to the CTLA4 region in an Italian IDDM data set. They furthermore analysed several (Italian, Spanish, UK, US and Sardinian) family data sets for association with the CTLA4 exon 1 polymorphism. Even though positive association was found only in the Italian and Spanish data set, combining all five data sets provided significant evidence for association of the G49 allele with IDDM. Marron et al 92 used a multi-ethnical approach in a large study of Asian, Mexican-American, French, Spanish and Caucasian-American case-control materials (Table 3) . None of the analysed case-control data sets showed evidence for association. However, significantly increased transmission of the G allele from heterozygous parents to diabetic children was found when they combined all the family-based studies, and the association was strengthened when the data were combined with the data from Nisticó et al. 41 Several studies have followed since then 40, 42, 43, [106] [107] [108] [135] [136] [137] analysing both the CTLA4 exon 1 and the 3ЈUTR polymorphism (Table  3) . Although there are some inconsistencies, CTLA4 polymorphisms have in most studies demonstrated an association with IDDM. 
Vitiligo
Vitiligo is a common skin disorder (affecting 1-2% of Americans) characterised by depigmentation. Vitiligo is often seen in patients who have one or more additional autoimmune diseases. 138 The aetiology of the disease is mainly unknown, but autoimmunity is likely to be involved. 139 Autoantibodies against tyrosinase 140, 142 and tyrosinase-related protein-2 143 have been demonstrated in patients with vitiligo. Several studies have reported associations of vitiligo with certain HLA specificities, but no consistent association with any of the HLA class I or class II alleles has been reported. [144] [145] [146] [147] Recently, the CTLA4 3ЈUTR polymorphism was investigated for association with disease in 74 UK patients with vitiligo 148 (Table 3 ). The frequency of the 106 bp allele was only increased in a subgroup of vitiligo patients suffering from an additional autoimmune disease, suggesting that vitiligo susceptibility by itself is not influenced by the CTLA4 3ЈUTR polymorphism.
Myasthenia gravis (MG)
The autoimmune process in myasthenia gravis results in postsynaptic blockade of neuromuscular conduction by autoantibodies directed against the acetylcholine receptor. 101 Thymic abnormalities such as hyperplasia and thymoma are common in MG. Thymic hyperplasia is more frequently found in female patients with early onset of disease while thymoma occurs in patients with late onset of the disease. 149 The prevalence of MG in the general population is 5-13 per 100 000. The incidence is age-and sex-related with one peak in the second and third decades affecting primarily females and a second peak in the sixth and seventh decade affecting primarily males. 150 Candidate genes for MG include the HLA, 151 immunoglobulin genes, 152 T cell antigen receptor genes 153 and the acetylcholine receptor gene. 154 Recently, association of the CTLA4 3ЈUTR with MG was investigated in 130 unrelated Swedish Caucasian patients 149 (Table 3) . However, only a subgroup of MG/thymoma patients have shown a higher prevalence of the 104 bp allele (denoted as the 106 bp allele in other studies) when compared with healthy controls.
Multiple sclerosis (MS)
Multiple sclerosis is a chronic demyelinating disease that affects the central nervous system. MS is pathologically characterised by perivascular mononuclear cell infiltrates preceding myelin loss. The cause of MS is unknown, but it has been suggested that the myelin damage is immunemediated, either secondary to a viral infection or a direct autoimmune process. The prevalence of MS varies between populations, the average prevalence is 0.1% in Caucasians of European ethnicity. The average age-atonset of MS is 28-30 years. 155 Epidemiological evidence provides support for a genetic basis to the development of MS. Increased familial risks range from 30% for monozygotic twins 156 to 3-4% for first-degree relatives. 157 The HLA association with MS is well documented. Several genome scans have been completed in MS. 57, 63, 83 Despite the lack of linkage of the CTLA4 region from the genomewide studies, CTLA4 has been suggested as a candidate gene for MS. The exon 1 polymorphism has been investigated in Swedish 38 and Norwegian studies 158 and some positive evidence for association 38, 158 and linkage 38 with MS was found (Table 3) . Ligers et al 38 also found an association of the C-318T polymorphism (Table 3) .
Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus is considered to be the prototype of human systemic autoimmune diseases. It is a disorder of generalised autoimmunity characterised by multi-organ involvement, polyclonal B cell activation, and production of autoantibodies against nuclear, cytoplasmic, and cell surface antigens. The tightly regulated process of programmed cell death (apoptosis) of autoreactive B and T lymphocytes in healthy individuals has been suggested to be impaired in SLE patients. The dysfunction of apoptosis may result in inappropriate longevity of autoreactive B lymphocytes, allowing the level of autoantibodies to reach pathogenic thresholds and breakdown of self tolerance. 159, 160 The prevalence of SLE is 0.2-0.3% in the general population. 101 SLE may occur at all ages, but the second to the fifth decade of life is the most common time for the disease to manifest. 101 As for many other autoimmune diseases, SLE susceptibility appears to be inherited in a polygenic fashion involving both environmental and genetic factors. A recent twin study found SLE concordance rates for monozygotic and dizygotic twins to be 24% and 2%, respectively. 161 The risk for siblings are found to be 2%. 162 Since multiple organ involvement in SLE pathology is seen, the list of candidate genes is almost endless. The MHC and other immune response genes have been the main target for intensive studies.
Due to the inhibitory role of the CTLA-4 molecule in the immune response and the frequently observed hyperactivities of both B and T lymphocytes in SLE, it is reasonable to speculate that defective expression of the CTLA-4 molecules in patients with SLE may be present. One study has investigated the expression of CTLA-4 molecules on freshly isolated T lymphocytes from patients with SLE. 163 Increased expression of the CTLA-4 molecule in T lymphocytes from SLE patients compared to controls was found, implying at least that T cells from patients with SLE possess the ability to express CTLA-4 molecules. Genetic studies have investigated the CTLA4 promoter, 110 the exon 1 164 and the 3ЈUTR polymorphisms 165 in UK Caucasian 110, 164 and MexicanAmerican 165 SLE materials. None of the studies found association between SLE and the CTLA4 polymorphisms (Table 3) .
Rheumatoid arthritis (RA)
Rheumatoid arthritis is a chronic inflammatory polyarthritis of unknown aetiology, characterised by remarkable hyperplasia of synovial lining cells, neovascularisation, and intense infiltration of mononuclear cells, predominantly CD4
+ T cells, in the synovium. 166, 167 These features, together with the presence of rheumatoid factor, an autoantibody against self IgG in the sera of most patients, indicate that RA is an autoimmune disease. The prevalence of RA in most populations studied is ෂ1%, with a 2 to 3-fold excess of females. Twin studies reflect the important contribution of genetic factors in RA as monozygotic twins are at least four times more likely (12-30%) to be concordant than dizygotic twins, who have a similar recurrence risk to their non-twin siblings. 168, 169 The occurrence of RA is strongly associated with the expression of particular HLA-class II alleles, however little is known about other genes involved in RA. 170, 171 Interestingly, one study has shown that the T cell response upon presentation of arthritogenic antigens to T cells by synovial dendritic cells can be blocked by CTLA4-Ig. 172 Recently, association of the CTLA4 exon 1 polymorphism with RA has been investigated in two case-control studies 173, 174 and a preliminary linkage study. 175 However, only specific CTLA4/HLA subgroups showed evidence for association (Table 3) .
Celiac disease (CD)
Celiac disease is a gluten-sensitive enteropathy characterised by small bowel mucosal atrophy. CD is not defined as a classical autoimmune disorder, but T-cell mediated immune response to immunodominant wheat gliadin (a Genes and Immunity component of gluten) peptides plays a crucial role in the disease. Ingestion of gluten-containing cereals induces immunologically mediated intestinal injury in genetically susceptible individuals. 176 The prevalence of CD in the Western World is between 0.2% and 0.5%. 177 However, this prevalence probably represents an underestimate, since not all cases of CD are symptomatic. Although the HLA component of celiac disease susceptibility is well characterised, [178] [179] [180] little is known about the possible role of other genes than HLA. It is likely, that one or more genes outside the HLA region may predispose to CD. Non-HLA genes may be important determinants of disease susceptibility, as indirectly shown by the high disease concordance rate in monozygotic twins (70%) 181 compared with only 30% in HLA identical siblings. 182 Blocking the T cell activation by CTLA4-Ig can control some but not all of the immunological features of CD in man. 183 Some evidence of association with disease was also found when the CTLA4 exon 1 polymorphism was investigated in a French case-control study. 184 Recently, a family-based linkage study of the CTLA4 region, including the exon 1 and the 3ЈUTR polymorphisms, found significant evidence for linkage to CD 185 (Table 3) .
Other disorders CTLA4 polymorphisms have been studied only in few other disorders. The majority of studies are so far preliminary. They include studies in viral hepatitis, 186 primary biliary cirrhosis 187 and primary sclerosing cholangitis. 188 A study in leprosy patients found complete absence of the 104 bp allele of the 3ЈUTR microsatellite in a small number of cases. 189 Finally, an interesting observation was made by Tsai et al, 190 who studied the role of the CTLA4 3ЈUTR microsatellite in idiopathic recurrent miscarriage. They found preferential transmission of maternally-inherited shorter alleles to live-born children, but random transmission of paternally-inherited alleles. Based on this observation the authors suggested that CTLA4 may be imprinted in man and that the gene may play a role in inducing or maintaining tolerance at the maternal-fetal interface.
Conclusions
There is accumulating evidence to suggest genetic contribution of the CTLA4 locus to a number of autoimmune diseases. From animal models of human autoimmunity there is convincing evidence that CTLA-4 may be of pathogenethically relevance in SLE, IDDM and MS. Genome scans in both human and rodent autoimmune diseases have shown some positive evidence for linkage of the chromosomal interval harbouring the CTLA4 locus in IDDM and SLE. A candidate gene approach has provided evidence for CTLA4-encoded susceptibility in IDDM, CD and AITD, whereas the picture is less clear with regard to RA. Based on data from animal models, expression studies in tissue from patients, and genome scans, it is somewhat surprisingly that no direct evidence for linkage and/or association to SLE has been found. Also, in MS, CTLA4 is a candidate gene. However, so far only two studies have investigated polymorphisms of the CTLA4 locus in MS. Clearly, more studies are needed to clarify the potential involvement of CTLA-4 in autoimmune diseases. Especially, more studies addressing the role of CTLA4 in the genetic susceptibility to SLE and MS are warranted. Efforts should be given to addressing this in family studies, which is a possible approach at least for SLE. Given the function of CTLA-4, it is surprisingly that no studies on the genetics of the CTLA4 locus and inflammatory bowel diseases, ie, Chron's disease and colitis ulcerosa, have been published.
Future strategies should include a more specific approach to the possible involvement of CTLA-4 in the pathogenetical process, eg by studying the CTLA-4 expression during disease development-rather than studying only ligand-receptor interaction-in the rodent spontaneous disease models. Finally, studies investigating the possible functional significance of the identified polymorphisms of the CTLA4 locus are needed to establish whether CTLA4 is a real disease gene.
